skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi 5i Team,

This is just a comment about today's market 6% decline. The Wall Street Journal published a scathing article today about drug makers who don't spend any money and on R&D and sky-rocket drug prices. In my opinion Concordia was unfairly criticized in the article as as being one of the worst offenders.

Thanks, Shane
Read Answer Asked by SHANE on November 23, 2015
Q: I think I may have experience a time out, so apologize if i have dupliacted this.
Not a question, but a comment in response to the posting of the Globe and Mail article referring to ``PHM in Steep decline``. First off, this article may be misleading to members as it was written on Oct.19th. The SP for PHM has increased since then and by roughly 30% in the last 5 days. I am quite pleased with this as I thought I was fortunate when I had a buying opportunity at $.63. You can imagine my chagrin when the price maintained its downward spiral and hit a low of $.44. I held for the same reason I bought. Despite the ugly series of events that precipitated the downward trend, I felt the fundamentals supported the thesis that this stock was unjustly oversold. I experienced the same scenario with Concordia. I excitedly bought CXR at $54. Then, out of a sense of recouping some of my loss, I bought at $45. We all know the story, and I feel fortunate to have bought my last lot at $30. By doing so, I was able to average my cost to $44. Today the stock is over $50. I only wish I had the fortitude to have bought at its ``bottom`` of $25. Needless to say, during a negative Market backdrop, I am thankful that I maintained my confidence in the fundamentals of these two stocks and feel they both have tremendous upside. Thank you to 5i for your guidance in teaching us to recognize true fundamentals, and my simple message to other new investors and members of 5i … try not to be overly swayed by all that is written by the `` Talking Heads``
Thank you, Rick
Read Answer Asked by Rick on November 19, 2015
Q: Before I logged into my account I was reading an article by Ryan about Concordia and half way through it, it said to read the rest or to read articles like this join 5i Research. I am a member so where would I find the rest of this article? I have a 200 shares at higher prices and I was thinking of averaging down to buy at between $38 and $40. Is that a good idea and where would I find the rest of this article on CXR? Thanks for keeping us posted on this situation. Dennis
Read Answer Asked by Dennis on November 08, 2015
Q: Hi Peter, At first I want to say that I did not listen to your advice on portfolio diversification and allocated 25% of my portfolio to Concordia by averaging down when it was going down. My average cost is CAD$44. I am now down 18% as CXR is down 8% today. I am very uncomfortable with this, I have other 46 stocks having 75% of my portfolio(most of them from your growth and balance portfolio) and then I have CXR which is 25% of my portfolio. Question to you is this: 1. Do you know why it is down today(could not find any news or downgrade)? 2. Is there any catalyst coming(except quarterly result on 10th November) 3. I see its volume is below average last couple of days, do you think professional money manager will buy this name again? Or how and why the price going to go up? 4. How do you want me unwind the position, I don't want to sell now as I am 18% down, should I sell when the price comes back up to my average cost? 5. I read the report by Ryan and all other analyst reports on CXR and it convinced me that there is significant upside to this name, so should I hold it? This is in my taxable margin account.
Read Answer Asked by Sridip on November 03, 2015
Q: I was reading the latest TD analyst report (dated Oct. 22, 2015) regarding CXR and was a bit frustrated that they significantly lowered the price target not because of the earnings expectations for the company but on overall sector valuations/conditions (I would say this was primarily driven by Valeant). It seems the report was reacting to recent market events (which can quickly turn around) more than anything else, and doesn't seem to take into consideration that there will be a guidance announcement this coming Monday Oct. 26. Thoughts?

On a side note, is there a way to obtain all analyst reports for a security without paying an exorbitant amount? I have access to TD reports because I trade through TD Direct Investing but not much else.
Read Answer Asked by Arneh on October 25, 2015
Q: Could you explain, in general terms, how companies like CXR (and I suppose VRX) actually thrive? CXR buys an existing company, but how do they become so successful? Do they somehow unlock synergies to cut costs or increase sales, or is it just price increases? Or is it that they somehow are able to purchase these companies at a great price, and if so, why would the existing owner sell at such a low price? CRX has levered itself to buy their most recent company, but why is this such a great deal? Thanks again for your insight!
Read Answer Asked by Donald on October 23, 2015
Q: Good day, I am not risk adverse and sometimes that can get me in trouble. This stock looks like it is overblown to the downside. I know you would never recommend it but if my Healthcare allocation is ~5%. Would now be a good time to load up, maybe beyond a full position in this stock, or is that too dangerous with it falling like it is? I am thinking just above 5% of my portfolio?
Read Answer Asked by Colin on October 21, 2015
Q: Regarding Maida's post on CINVEN buying 7.2M shares today. Is that news accurate. I've been trying to find any news on internet (incl. their webpage) to no avail. Someone at stockhouse.com says news came from Reuters (couldn't find anything). Have you guys verified this? If so, maybe you can provide the link.
Thank you!
Read Answer Asked by Silvia on October 21, 2015
Q: My apologies for adding to the barrage of questions on Concordia -- I promise to sit on my hands on any further questions until the end of the year. Pinky swear : )

Now, what validity should be attached to the Citron Research report? Is it factual? Is it accurate? Is it truthful -- three very distinct entities, from a legal perspective.

More importantly, what's Citron's vested interest in all this?

From my understanding, the prime researcher on this is a renowned short-seller, so is this report as obvious a ploy as it looks?

Being naive? Or conspiratorial?

I'm just not sure what to believe anymore. I'm holding on to my shares for now, in this gale-force wind, because 5 I reiterates that there is value in the stock and that the fundamentals will speak for themselves, if we can hang on through all this noise.

Thanks for your advice, as always.

Read Answer Asked by Sylvia on October 21, 2015
Q: Do you think that the fundamental profit drivers of Concordia have changed? CXR has borrowed lots of money to make acquisitions based on the assumption that they can increase drug prices. The CEO of Valiant seems to be suggesting this pricing power might be gone. Since CXR is a highly leveraged play, maybe the fundamental are not nearly as good in this new drug pricing environment?
Read Answer Asked by Kent on October 21, 2015
Q: Hi Peter and Team,
When Jason Donille was on BNN's Market Call a day or two ago, he commented that as a result of the recent plunge in its share price to $40, CXR's PE ratio has now dropped to 4x. But according RBC's web site, at today's closing price of $35.33, CXR has a PE ratio of 52.2x. Would you please comment on this huge discrepancy between the 2 PE ratios as quoted on BNN and RBC's web site, respectively.

Regards,

H.S.
Read Answer Asked by Harry on October 21, 2015
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!